In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.
Vinay Prasad has departed the Center for Biologics Evaluation and Research for the second time in less than a year. The leadership shift at the U.S. Food and Drug Administration comes amid continued scrutiny of regulatory priorities related to biologics, vaccines, and gene therapies. Industry observers say the move underscores the evolving leadership dynamics at one of the agency’s most influential divisions.
In deal news, GSK and Alfasigma have entered a licensing agreement centered on a therapy being developed for liver disease. Meanwhile, Servier has agreed to acquire Day One Biopharmaceuticals in a deal valued at approximately $2 billion. The transactions highlight continued consolidation and partnership activity as companies strengthen pipelines through external innovation.
Finally, Ipsen has withdrawn Tazverik from the market following emerging data from ongoing clinical trials. The decision reflects shifting risk–benefit considerations as new evidence becomes available, illustrating the ongoing evaluation required for oncology therapies even after regulatory approval.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
